Navigation Links
Divine Corporation's Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
Date:1/22/2008

An Independent Study by the National Cancer Institute Revealed Divine No. 9 and Divine No. 8 to be Highly Effective in Inhibiting Viruses that Cause

Cervical, Vaginal and Anal Cancers in vitro

ORLANDO, Fla., Jan. 22 /PRNewswire/ -- Divine Corporation announced today an unprecedented discovery in personal lubricants that promises to revolutionize the market. The National Cancer Institute's Laboratory of Cellular Oncology has completed a laboratory study of Divine Corporation's No. 9 and No. 8 personal lubricants and determined they are highly effective in blocking infection by certain strains of human papillomaviruses (HPVs) that have been proven to cause cervical, vaginal and anal cancers [1]. Divine No. 9 and Divine No. 8 personal lubricants now offer the possibility of HPV protection while at the same time enhancing the pleasure of intimate contact.

"We began by combining natural ingredients to create the best performing intimate lubricant on the market; one that would have unique and delightful play characteristics and feel great on your skin," said Stephanie Fresonke, President of Divine Corporation. "Thanks to the breakthrough work of the National Cancer Institute research team, Divine has now been shown to be an extremely potent human papillomavirus inhibitor in their laboratory studies. While clinical tests have not yet been performed, it is tremendously exciting to offer our customers the possibility to combine pleasure and protection in a single bottle."

Divine's unique formulations include an array of natural ingredients, most notably an extract from sea kelp called carrageenan. The National Cancer Institute study, "Carrageenan is a Potent Inhibitor of Papillomavirus Infection," has shown carrageenan to be an extremely effective topical microbicide for a broad range of sexually transmitted HPVs in vitro. The experiments compared a range of consumer products containing carrageenan. Divine No. 8 and Divine No. 9 proved to be the most potent virus inhibitors of any product in the study, blocking HPV infectivity even when diluted a million-fold.

[1] Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, et al. (2006) Carrageenan Is a Potent Inhibitor of Papillomavirus Infection. PLoS Pathog 2(7): e69 doi:10.1371/journal.ppat.0020069

About Divine Corporation

Divine Corporation is dedicated to making intimate situations as safe and enjoyable as they possibly can be. Intensive research has led to a line of products formulated with natural ingredients that are shown to block life- altering viruses in independent laboratory studies. In addition, both unscented Divine No. 9 and vanilla-scented Divine No. 8 are known for their exotic, slippery feel that dries clean, never sticky. Look for Divine personal lubricants in health food stores, on-line drugstores such as Drugstore.com, and other discriminating websites. Learn more at http://www.divinetimes.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Debbie Gallaher, +1.407.468.4228, debbie@divinetimes.com


'/>"/>
SOURCE Divine Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
2. Personalized Medicine - The Genomic Revolution in Cardiac Care
3. SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
4. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
5. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
6. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
9. Northwestern Memorial Transplant Program Initiates New Study
10. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):